Cladribine tablets for treating relapsing–remitting multiple sclerosis - guidance (TA493)

Source:
National Institute for Health and Care Excellence - NICE
Publication date:
06 December 2017

Abstract

Evidence-based recommendations on cladribine tablets (Mavenclad) for treating highly active relapsing–remitting multiple sclerosis in adults.

Guidance development process

How we develop NICE technology appraisal guidance

Next review: December 2020